头颈癌淋巴结转移数目与肿瘤学结局:NRG/RTOG 9501、NRG/RTOG 0234和EORTC 22931的二次分析
该研究对3项前瞻性随机对照试验中947例接受手术及术后放疗±全身治疗的头颈鳞癌患者进行二次分析,评估病理阳性淋巴结数目与复发模式及死亡的关系。多变量分析显示,总生存和无病生存随阳性淋巴结数目增加而持续下降,局部区域复发风险在阳性淋巴结≤5枚时急剧上升、超过5枚后趋于平稳,而远处转移风险随阳性淋巴结数目持续增加。
要点
- 在高危已切除头颈鳞癌中,死亡风险随病理阳性淋巴结数目增加而升高。
- 阳性淋巴结≤5枚时局部区域复发风险急剧上升,超过5枚后趋于平稳。
- 远处转移风险随阳性淋巴结数目持续增加,与局部区域复发模式不同。
核心结论
- 在高危已切除头颈鳞癌中,死亡风险增加与阳性淋巴结数目增加相关。
- 局部区域复发和远处转移风险在阳性淋巴结≤5枚时平行增加,但仅远处转移风险在阳性淋巴结进一步增加时持续上升。
- 这些不同的复发模式有助于为未来治疗设计提供信息。
研究设计与样本
- 对3项前瞻性随机对照试验(RTOG 9501、RTOG 0234、EORTC 22931)中947例接受手术及术后放疗±全身治疗的头颈鳞癌患者进行二次分析。
- RTOG 9501纳入410例,RTOG 0234纳入203例,EORTC 22931纳入334例。
- 构建总生存、无病生存、局部区域复发和远处转移的多变量模型,并使用限制性立方样条模拟阳性淋巴结数目与结局的非线性关系。
主要发现
- 多变量分析中,总生存随每个阳性淋巴结增加而下降且无平台期,在≤5枚阳性淋巴结时最明显(HR 1.21/每个阳性淋巴结;95%CI 1.10-1.34;P<.001),超过5枚后下降趋缓(HR 1.02/每个阳性淋巴结;95%CI 1.01-1.06;P<.001)。
- 无病生存随每个阳性淋巴结增加而下降且无平台期,在≤5枚阳性淋巴结时最明显(HR 1.19/每个阳性淋巴结;95%CI 1.08-1.30;P<.001),超过5枚后下降趋缓(HR 1.04/每个阳性淋巴结;95%CI 1.02-1.06;P<.001)。
- 局部区域复发风险在≤5枚阳性淋巴结时急剧上升(HR 1.28/每个阳性淋巴结;95%CI 1.10-1.50;P<.001),超过5枚后趋于平稳(HR 1.00/每个阳性淋巴结;95%CI 0.96-1.04;P=.98)。
- 远处转移风险随阳性淋巴结数目持续增加(≤5枚:HR 1.10/每个阳性淋巴结;95%CI 1.01-1.20;P=.04;>5枚:HR 1.05/每个阳性淋巴结;95%CI 1.02-1.08;P=.003)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A better understanding of the relationship between the spread of head and neck squamous cell carcinoma (HNSCC) to regional lymph nodes (LNs) and the frequency and manner of treatment failure should help design better treatment intensification strategies. In this study, we evaluated the relationship between recurrence patterns, mortality, and number of pathologically positive (+) LNs in HNSCC in 3 prospective randomized controlled trials. METHODS AND MATERIALS: We performed a secondary analysis of 947 patients with HNSCC enrolled in RTOG 9501 (n = 410), RTOG 0234 (n = 203), and EORTC 22931 (n = 334) undergoing surgery and postoperative radiation ± systemic therapy. Multivariable models were constructed for overall survival (OS), disease-free survival (DFS), locoregional relapse (LRR), and distant metastases (DM). Restricted cubic splines were used to model the nonlinear relationship between +LN number and outcomes. RESULTS: In multivariable analysis, OS and DFS decreased with each +LN without plateau, most pronounced up to 5 +LNs (OS: hazard ratio [HR], 1.21 per +LN; 95% confidence interval [CI], 1.10-1.34; P < .001; DFS: HR per +LN, 1.19; 95% CI, 1.08-1.30; P < .001) and more gradually beyond this (OS: HR per +LN, 1.02; 95% CI, 1.01-1.06; P < .001; DFS: HR per +LN, 1.04; 95% CI, 1.02-1.06; P < .001). In contrast to LRR risk, which increased sharply up to 5 +LNs (HR per +LN, 1.28; 95% CI, 1.10-1.50; P < .001) but plateaued beyond this (HR per +LN, 1.00; 95% CI, 0.96-1.04; P = .98), DM risk increased continuously with increasing +LNs (≤5 +LNs: HR per +LN, 1.10; 95% CI, 1.01-1.20; P = .04; >5 +LNs: HR per +LN, 1.05; 95% CI, 1.02-1.08; P = .003). CONCLUSIONS: In high-risk resected HNSCC, increased mortality was associated with increased +LN count. LRR and DM risk both increased in parallel up to 5 +LNs, but only DM continued to increase for further +LN increases. These differing recurrence patterns can help inform design of future treatments.
引用
- Lu DJ, Luu M, Gay C, et al. Nodal Metastasis Count and Oncologic Outcomes in Head and Neck Cancer: A Secondary Analysis of NRG/RTOG 9501, NRG/RTOG 0234, and EORTC 22931. Int J Radiat Oncol Biol Phys. 2022. PMID: 35395358. doi:10.1016/j.ijrobp.2022.03.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。